Published in Front Oncol on November 15, 2013
Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer (2015) 1.00
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs (2014) 0.87
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun (2016) 0.80
BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget (2016) 0.78
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol (2016) 0.77
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. J Korean Med Sci (2017) 0.75
Towards a molecular classification of colorectal cancer. Front Oncol (2015) 0.75
Lack of BRAFV600E mutation in stage I and II of colorectal cancer. Gastroenterol Hepatol Bed Bench (2016) 0.75
When to screen and not to screen. Cancer Biol Ther (2014) 0.75
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell Int (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol (2009) 4.94
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 2.79
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 2.53
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Association between a high number of isolated lymph nodes in T1 to T4 N0M0 colorectal cancer and the microsatellite instability phenotype. Arch Surg (2010) 2.26
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res (2011) 2.22
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res (2013) 2.03
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol (2010) 2.00
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg (2009) 1.73
Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol (2013) 1.59
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Targets of Raf in tumorigenesis. Carcinogenesis (2010) 1.46
Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet (2012) 1.45
BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum (2012) 1.42
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 1.40
RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun (2010) 1.37
A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell (2013) 1.35
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 1.33
Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One (2013) 1.29
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res (2013) 1.21
Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology (2013) 1.21
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol (2013) 1.16
BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 1.16
BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer (2013) 1.14
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 1.12
Clinicopathological relevance of BRAF mutations in human cancer. Pathology (2013) 1.11
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol (2010) 1.08
The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One (2013) 1.08
Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer (2013) 1.06
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer (2013) 1.01
Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. Mol Med (2013) 1.00
BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch (2013) 0.96
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res (2013) 0.95
Receptor tyrosine kinases in cancer escape from BRAF inhibitors. Cell Res (2012) 0.88
Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol (2013) 0.87
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol (2012) 0.84
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res (2005) 1.46
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Intussusception and spontaneous amputation of the esophagus. J Thorac Cardiovasc Surg (2002) 1.38
Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol (2002) 1.35
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res (2005) 1.34
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol (2006) 1.27
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Gastric cancer: basic aspects. Helicobacter (2012) 1.11
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res (2004) 1.11
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2011) 1.10
Candidate driver genes in microsatellite-unstable colorectal cancer. Int J Cancer (2011) 1.08
Gastric cancer: basic aspects. Helicobacter (2011) 1.08
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol (2009) 1.06
Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat (2005) 1.06
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer (2003) 1.05
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res (2008) 1.05
Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. J Biol Chem (2005) 1.02
Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter (2010) 1.01
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol (2009) 1.00
CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther (2012) 0.97
BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch (2013) 0.96
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J Gene Med (2009) 0.96
Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. Gastroenterology (2013) 0.92
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat (2005) 0.92
VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer (2006) 0.92
Targeted therapy in gastric cancer. APMIS (2015) 0.91
Serrated polyps of the colon: how reproducible is their classification? Virchows Arch (2012) 0.91
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res (2003) 0.91
Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther (2007) 0.91
Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Rev (2011) 0.90
Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol (2005) 0.90
Prognostic significance of cyclin A in gastric cancer. Int J Cancer (2006) 0.90
HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biol (2010) 0.89
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med (2007) 0.88
Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer (2014) 0.87
Basic aspects of gastric cancer. Helicobacter (2009) 0.87
Retracted Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol (2003) 0.87
Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol (2005) 0.87
Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol (2011) 0.85
Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. Fam Cancer (2015) 0.84
Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncol Rep (2006) 0.83
Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS. Mol Ther (2011) 0.83
Expression of HuR in Merkel cell carcinoma and in normal skin. J Cutan Pathol (2008) 0.82
Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res (2013) 0.82
VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch (2014) 0.82
Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clin Gastroenterol Hepatol (2008) 0.81
High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint. Carcinogenesis (2010) 0.81
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses. PLoS One (2008) 0.80
Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer (2005) 0.79
Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. Histopathology (2013) 0.79
Cause of death during long-term follow-up for superficial esophageal adenocarcinoma. Ann Surg Oncol (2013) 0.78
Ewing's sarcoma family of tumors in Finland during 1990-2009: a population-based study. Acta Oncol (2012) 0.78
Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res (2008) 0.78
Tumor suppressor effect of the microRNA miR-519 is mediated via the mRNA-binding protein HuR. Cell Cycle (2010) 0.77
Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer (2011) 0.77
Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human fetal intestine. Pediatr Res (2007) 0.76
Smad4 haploinsufficiency: a matter of dosage. Pathogenetics (2008) 0.76
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity. J Gene Med (2008) 0.75
[Coxibs in treatment and prevention of cancer]. Duodecim (2005) 0.75
[From animal models to human trials of Peutz-Jeghers syndrome]. Duodecim (2004) 0.75
[Targeted therapy of a cancer patient is multiprofessional collaboration]. Duodecim (2013) 0.75
Cyclooxygenase-2 expression in primary Merkel cell carcinoma. J Cutan Pathol (2005) 0.75
[Multidisciplinary tailoring of therapy of metastatic colon cancer]. Duodecim (2016) 0.75
Cyclooxygenase-2 expression in human soft-tissue sarcomas is related to epithelial differentation. Anticancer Res (2005) 0.75
[What will determine the first-line treatment of a patient with rectal cancer?]. Duodecim (2016) 0.75
[Changing prognosis and treatment of gastric cancer]. Duodecim (2010) 0.75
[Radio frequency ablation of Barrett's esophagus--can the risk of esophageal adenocarcinoma be reduced?]. Duodecim (2014) 0.75
Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin. Int J Colorectal Dis (2014) 0.75